Impact of brand differentation on life sciences market competition

14 May 2006

A newly-released study from BioInformatics evaluates brand differences among 17 leading brands in the US life science supply market and customer perceptions about competitors.

According to consumers, Affymetrix was considered the most differentiated brand. Life scientists cited its performance in innovation as an important strategic advantage, the study says. New England Biolabs was perceived to have the best products according to respondents, who also considered the company to have a very sincere "brand personality." Nonetheless, it notes, Invitrogen maintained the strongest bond with its customers and garnered the highest marks in customer service and technical support.

For each company, the report reveals blocks of consumers that are vulnerable to acquisition by competitors emphasizing which are the most sought after brand attributes. Brands that appeal to these needs can maximize market share by earning the allegiances of customer segments from close competitors through brand differentiation, it states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight